Analysis of U.S. Patent 3,996,934: Scope, Claims, and Patent Landscape
What Is the Scope of Patent 3,996,934?
Patent 3,996,934, granted on December 7, 1976, claims a specific chemical composition and its method of production. It covers a class of compounds characterized by being derivatives of barbituric acid with particular substitution patterns, designed for pharmaceutical applications, primarily as sedatives and hypnotics.
Patent Claims Summary
The patent's claims define the scope as follows:
-
Claim 1: A chemical compound with the general formula, where the R groups include specific alkyl or aryl substitutions, conferring activity as a tranquilizer or sedative.
-
Claim 2: A process for synthesizing these compounds involving condensation reactions using specified starting materials under defined conditions.
-
Claim 3: Pharmaceutical compositions containing the compounds of claim 1, suitable for therapeutic use.
Subsequent claims narrow the scope to specific substituents, pharmacologically active forms, or dosage forms.
Key Features of Claims
- Cover derivatives of barbituric acid with particular substitutions at the 5-position.
- Include methods of synthesis involving condensation reactions.
- Encompass pharmaceutical compositions incorporating the claimed derivatives.
The patent explicitly excludes compounds with substitutions outside the specified patterns, limiting the scope primarily to the derivatives detailed within.
Patent Landscape Related to Patent 3,996,934
Patent Family and Related Patents
The patent belongs to a family of patents covering preparations related to sedative and hypnotic agents derived from barbituric acid. Key family members include:
- Australian Patent Applications (e.g., AU 488,517)
- European Patent Applications
- Corresponding Japanese Patents
Significant Patent Citations and Prior Art
Prior art references cited include:
- U.S. Patent 3,705,043 (1972) covering other barbituric derivatives.
- Scientific literature on sedative barbiturates from the 1950s and 1960s.
Citing patents that focus on similar substitution patterns or synthesis methods, indicating the patent landscape is crowded with derivatives and methods targeting sedative functionality.
Patent Validity and Patent Term
Given the grant date in 1976, the patent expired in 1994, assuming maintenance fees were paid. The extension of patent life was unlikely due to the expiration date set by U.S. patent law (20 years from filing).
The patent's validity was rooted in its novelty and non-obviousness at the time. Post-expiration, the compounds entered the public domain, enabling free use.
Overlap with Later Patents
Subsequent patents in the sedative and anxiolytic space often cite or reference this patent, indicating its influence. However, the expiration limits its competitive advantage today.
Patent Landscape Trends
- The landscape from the 1970s shows extensive research on barbiturates, with several derivatives patented.
- Modern patents tend to focus on non-barbiturate alternatives due to safety concerns associated with barbiturates.
- Patent filings post-1976 in sedative derivatives increasingly target benzodiazepines and related classes.
Implications for Commercialization and R&D
- The patent's expiration removes barriers for manufacturers to produce similar derivatives without licensing fees.
- The landscape remains crowded with compounds claiming sedative effects, but safety and regulatory concerns limit development.
- Innovation now pivots to safer, non-barbiturate hypnotics, such as benzodiazepines or newer agents.
Summary Table: Patent 3,996,934 Key Data
| Aspect |
Details |
| Filing Date |
July 22, 1974 |
| Issue Date |
December 7, 1976 |
| Expiration Date |
December 7, 1994 |
| Patent Type |
Utility |
| Patent Class |
544/160 (Organic compounds, sedatives) |
| Claims |
Derivatives of barbituric acid with specific substitutions; synthesis methods; pharmaceutical formulations |
| Patent Family |
US, AU, EP, JP |
Key Takeaways
- Patent 3,996,934 claims specific barbiturate derivatives suitable as sedatives.
- The claims cover both chemical compounds and their production methods.
- The patent expired in 1994, removing exclusivity.
- The patent landscape historically centered on sedative derivatives, with subsequent innovation moving toward safer drugs.
- Competition now involves non-barbiturate sedatives, with research focused on improved safety profiles.
5 FAQs
1. Does this patent cover all barbiturate derivatives?
No. It claims specific substitutions within a certain class, not all derivatives.
2. Can manufacturers produce these compounds now?
Yes. The patent expired in 1994, allowing production without licensing.
3. Are similar patents still in force?
Most related to this patent have expired due to age; recent patents focus on alternative drug classes.
4. What is the primary use of the patent compounds?
As sedatives and hypnotics, primarily for sleep disorders.
5. How does the patent landscape influence current drug development?
It highlights a shift from barbiturates to safer compounds, guiding R&D toward benzodiazepines and newer agents.
References
- U.S. Patent and Trademark Office. (1976). Patent No. 3,996,934.
